LBA50 ACTIVE: Apatinib plus gefitinib versus placebo plus gefitinib as first-line treatment for advanced epidermal growth factor receptor-mutant (EGFRm) non-small-cell lung cancer (NSCLC): A multicentered, randomized, double-blind, placebo-controlled phase III trial (CTONG1706)

Annals of Oncology ◽

10.1016/j.annonc.2020.08.2283 ◽

2020 ◽

Vol 31 ◽

pp. S1181

Author(s):

L. Zhang ◽

H. Zhao ◽

Z. Zhang ◽

W. Yao ◽

X. Min ◽

...

Keyword(s):

Growth Factor Receptor ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

First Line ◽

Double Blind ◽

Phase Iii Trial ◽

Epidermal Growth ◽

Receptor Mutant ◽

First Line Treatment

Download Full-text

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

Yearbook of Oncology ◽

10.1016/j.yonc.2011.08.001 ◽

2011 ◽

Vol 2011 ◽

pp. 33-34

Author(s):

J.T. Thigpen

Keyword(s):

Growth Factor Receptor ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Epidermal Growth ◽

Locally Recurrent ◽

First Line Treatment

Download Full-text

A multi-center, randomized, double-blind, parallel, two-group phase III trial on the efficacy and safety of QL1101 or bevacizumab in combination with paclitaxel and carboplatin in first-line treatment of non-squamous non-small cell lung cancer

Annals of Oncology ◽

10.1093/annonc/mdy442 ◽

2018 ◽

Vol 29 ◽

pp. ix121 ◽

Cited By ~ 1

Author(s):

B. Han ◽

K. Li ◽

T. Chu ◽

M. Bi ◽

H. Zhang ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Efficacy And Safety ◽

Small Cell Lung ◽

First Line ◽

Double Blind ◽

Phase Iii Trial ◽

First Line Treatment

Download Full-text

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

Breast Diseases A Year Book Quarterly ◽

10.1016/j.breastdis.2011.10.016 ◽

2011 ◽

Vol 22 (4) ◽

pp. 412-413

Author(s):

A. Brufsky

Keyword(s):

Growth Factor Receptor ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Epidermal Growth ◽

Locally Recurrent ◽

First Line Treatment

Download Full-text

Vandetanib Versus Placebo in Patients With Advanced Non–Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR)

Yearbook of Oncology ◽

10.1016/j.yonc.2012.07.001 ◽

2012 ◽

Vol 2012 ◽

pp. 188-189

Author(s):

A.S. Tsao

Keyword(s):

Receptor Tyrosine Kinase ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Double Blind ◽

Phase Iii Trial ◽

Prior Therapy ◽

Epidermal Growth

Download Full-text

118TiP A multicenter, randomized, double-blind, placebo-controlled phase III trial of camrelizumab plus chemotherapy with or without radiation therapy (RT) as first-line treatment for patients with brain metastatic non-small cell lung cancer (BM-NSCLC; CTONG2003): Trial in progress

Annals of Oncology ◽

10.1016/j.annonc.2021.10.136 ◽

2021 ◽

Vol 32 ◽

pp. S1426-S1427

Author(s):

J. Yang ◽

Y. Pan ◽

F. Ning ◽

L. Lin ◽

X. Hu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

First Line Treatment

Download Full-text

RIBBON-1: Randomized, Double-blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

Yearbook of Medicine ◽

10.1016/s0084-3873(11)00187-8 ◽

2011 ◽

Vol 2011 ◽

pp. 121-122

Author(s):

J.T. Thigpen

Keyword(s):

Growth Factor Receptor ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Epidermal Growth ◽

Locally Recurrent ◽

First Line Treatment

Download Full-text

Comparison Between Second- and Third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as First-line Treatment in Patients With Non-small-cell Lung Cancer: A Retrospective Analysis

Anticancer Research ◽

10.21873/anticanres.15331 ◽

2021 ◽

Vol 41 (10) ◽

pp. 5137-5145

Author(s):

SHO MITSUYA ◽

KENJIRO TSURUOKA ◽

KIYOE KANAOKA ◽

TOMOYA FUNAMOTO ◽

HIROYUKI TSUJI ◽

...

Keyword(s):

Receptor Tyrosine Kinase ◽

Kinase Inhibitors ◽

Growth Factor Receptor ◽

Small Cell ◽

Third Generation ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

Receptor Tyrosine Kinase Inhibitors ◽

First Line Treatment

Download Full-text

First-line osimertinib in patients with epidermal growth factor receptor–mutant non–small-cell lung cancer and with a coexisting low allelic fraction of Thr790Met

European Journal of Cancer ◽

10.1016/j.ejca.2021.09.039 ◽

2021 ◽

Vol 159 ◽

pp. 174-181

Author(s):

Margarita Majem ◽

Ivanna Sullivan ◽

Santiago Viteri ◽

Guillermo López-Vivanco ◽

Manuel Cobo ◽

...

Keyword(s):

Lung Cancer ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

Receptor Mutant ◽

Allelic Fraction

Download Full-text

EECONOMIC EVALUATION OF AFATINIB AS THE FIRST LINE TREATMENT IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) LOCALLY ADVANCED OR METASTATIC IN PRESENCE OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS IN A MEXICAN INSTITUTIONAL CONTEXT

Value in Health ◽

10.1016/j.jval.2015.03.1179 ◽

2015 ◽

Vol 18 (3) ◽

pp. A307

Author(s):

J.L. Huicochea-Bartelt ◽

X. Burbano ◽

E. Palacios ◽

S. Herran ◽

C. Valencia

Keyword(s):

Locally Advanced ◽

Growth Factor Receptor ◽

Institutional Context ◽

Small Cell ◽

Egfr Mutations ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

Pharmacoeconomic analysis of Giotrif® (afatinib) as first-line treatment of metastatic non-small cell lung cancer with Del19 mutation of epidermal growth factor receptor (EGFR) gene

Malignant tumours ◽

10.18027/2224-5057-2015-4-35-47 ◽

2015 ◽

pp. 35 ◽

Cited By ~ 1

Author(s):

Vera Andreevna Gorbunova ◽

Sergey Vladimirovich Orlov ◽

Sergey Kensarinovich Zyryanov ◽

Dmitriy Yuryevich Belousov

Keyword(s):

Lung Cancer ◽

Pharmacoeconomic Analysis ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Egfr Gene ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text